AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 258: E1014-E1019, 1990;
0193-1849/90 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caufriez, A.
Right arrow Articles by Copinschi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caufriez, A.
Right arrow Articles by Copinschi, G.

AJP - Endocrinology and Metabolism, Vol 258, Issue 6 E1014-E1019, Copyright © 1990 by American Physiological Society


ARTICLES

Placental growth hormone as a potential regulator of maternal IGF-I during human pregnancy

A. Caufriez, F. Frankenne, Y. Englert, J. Golstein, F. Cantraine, G. Hennen and G. Copinschi
Department of Obstetrics and Gynaecology, Free University of Brussels, Belgium.

Ninety-three healthy women were investigated during normal pregnancy, and 177 blood samples were obtained at various gestational stages. In 8 of the women, serial measurements were obtained over a period of 16-34 wk from 8 to 40 wk of gestation. In 13 women, daily blood samples were obtained from day 0 to day 6 after delivery. Insulin-like growth factor I (IGF-I) and human placental lactogen (hPL) were measured by radioimmunoassays. Growth hormone (GH) was estimated by two monoclonal antibody-based radioimmunoassays insensitive to physiological concentrations of hPL: the K24 assay, which recognizes only pituitary hGH, and the 5B4 assay, which reacts with all the known pituitary as well as placental GH variants. Placental GH was distinguished from the main pituitary variant through its specific immunoreactivity pattern. Mean plasma levels of IGF-I were relatively stable until 29-30 wk gestation, then increased progressively to reach a maximum at 35-36 wk. Regardless of gestational age, individual IGF-I values exhibited a highly significant positive correlation with placental GH, reflected by 5B4 immunoreactivity, whereas the correlation between IGF-I and hPL was not statistically significant. Considering each 2-wk gestational period separately, we found a positive correlation between IGF-I and 5B4 hGH at 31-32 wk. Conversely, no evidence of correlation was found between IGF-I and hPL at any period. After delivery, IGF-I evolution exhibited a biphasic pattern, with an initial decrease to low values followed by a progressive return toward levels found in nonpregnant healthy women. These results strengthen our previous hypothesis that placental growth hormone is involved in the control mechanism of serum IGF-I levels in normal pregnant women.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. P. Lomenick, M. A. Hubert, and S. Handwerger
Transcription factor FOXF1 regulates growth hormone variant gene expression
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E947 - E951.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R.P. Holmes, J.M.P. Holly, and P.W. Soothill
Maternal serum insulin-like growth factor binding protein-2 and -3 and fetal growth
Hum. Reprod., July 1, 1999; 14(7): 1879 - 1884.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online